ibalizumab-uiyk (Trogarzo)
Jump to navigation
Jump to search
Indications
- multidrug-resistant HIV1 infection (FDA-approved March 2018)
Dosage
- IV infusion every 14 days
Adverse effects
More general terms
References
- ↑ Brown T FDA Approves Ibalizumab for Multidrug-Resistant HIV-1. Medscape - Mar 06, 2018. https://www.medscape.com/viewarticle/893512
FDA News Release. March 6, 2018 FDA approves new HIV treatment for patients who have limited treatment options. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm599657.htm